Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine

Share Article

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology in the study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies,” published Aug. 31, 2018.

Flagship Biosciences logo

Flagship Biosciences logo

“Flagship is proud to partner with pharmaceutical and biotech companies in the development of digital image analysis solutions, like MuscleMap, that support the treatment of challenging medical conditions such as DMD.” ~Trevor D. Johnson, Flagship Biosciences CEO

Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies,” was published in the Archives of Pathology & Laboratory Medicine on August 31, 2018. Download the study here: https://bit.ly/2wMyIVb

Duchenne muscular dystrophy (DMD) is a rare, progressive, and fatal neuromuscular disease caused by dystrophin protein loss in muscle. To support investigational treatment approaches, Flagship applied its expertise and proprietary technology in digital tissue image analysis to develop an immunofluorescent scanning and digital image-analysis solution that enables analysis of all muscle fibers within a biopsy section as well as providing data on each individual fiber.

To validate the MuscleMap approach, the study compared high-powered microscopic field total fiber counts and dystrophin-positive fiber counts obtained by trained pathologists to data produced by the MuscleMap algorithm. The authors note that this work is the first to validate immunofluorescent scanning and digital tissue image analysis workflow with the rigor required to support clinical trials.

“These exciting results will support more effective clinical trials for examining myofibers dystrophin expression by driving a greater level of consistency and detail,” says Trevor D. Johnson, Flagship Biosciences CEO. “Flagship is proud to partner with pharmaceutical and biotech companies in the development of digital image analysis solutions, like MuscleMap, that support the treatment of challenging medical conditions such as DMD.”

Download the study here: https://bit.ly/2wMyIVb

About Flagship Biosciences
Flagship Biosciences Inc. delivers comprehensive tissue profiling for predictive diagnostics in drug therapy using an Artificial Intelligence (AI) enabled computational tissue analysis (cTA®) pathology analytics platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients. For more information on how Flagship accelerates drug development, please visit http://www.flagshipbio.com and follow Flagship on Twitter @FlagshipBio.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sales and Laboratory
@FlagshipBio
Follow >
Flagship Biosciences, Inc.

Visit website